Showing results (41-50 of 68) with videos related to
Sort By:
Pageof 7
The Lancet. Oncology|October 14, 2019
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trialTheodore W Laetsch, Gary Douglas Myers, André Baruchel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2022
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA TrialTheodore W Laetsch, Shannon L Maude, Susana Rives, et al.Blood Advances|November 27, 2024
Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUMKrzysztof Kalwak, Laura M Moser, Ulrike Pötschger, et al.British Journal of Haematology|November 9, 2023
Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workupSenthilkumar Ramamoorthy, Dirk Lebrecht, Denny Schanze, et al.Nature Medicine|October 3, 2018
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemiaElena J Orlando, Xia Han, Catherine Tribouley, et al.Blood|March 16, 2025
HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective studyQuentin Riller, Mathias Hauri, Su Han Lum, et al.Hemasphere|November 3, 2025
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS studyAndré Baruchel, Karsten Nysom, Hyoung Jin Kang, et al.Journal for Immunotherapy of Cancer|August 6, 2021
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemiaJohn E Levine, Stephan A Grupp, Michael A Pulsipher, et al.Bone Marrow Transplantation|January 31, 2018
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)Peter Bader, Zyrafete Kuçi, Shahrzad Bakhtiar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2020
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III StudyChristina Peters, Jean-Hugues Dalle, Franco Locatelli, et al.Pageof 7